Loading…
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $170M | $-133M | $-194M | $-126M | -188.7% | 104.5% | -14.6% |
| 2024 | $83M | $-198M | $-227M | $-176M | -87.5% | -7.7% | -13.8% |
| 2023 | $90M | $-239M | $-263M | $-228M | -84.5% | -19.9% | -6.0% |
| 2022 | $113M | $-244M | $-280M | $-238M | -54.3% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 112.72 | 90.24 | 83.33 | 170.44 |
| Operating Revenue | - | 112.72 | 90.24 | 83.33 | 170.44 |
| Cost Of Revenue | - | 54.54 | 37.21 | 33.57 | 20.30 |
| Gross Profit | - | 58.18 | 53.03 | 49.76 | 150.14 |
| Operating Expense | - | 321.06 | 321.16 | 281.01 | 311.34 |
| Research And Development | - | 242.45 | 232.27 | 208.52 | 228.30 |
| Selling General And Administration | - | 85.28 | 88.49 | 76.62 | 82.86 |
| Total Expenses | - | 375.60 | 358.37 | 314.57 | 331.64 |
| Operating Income | - | -262.88 | -268.13 | -231.24 | -161.20 |
| Total Operating Income As Reported | - | -262.88 | -268.13 | -233.35 | -161.20 |
| EBITDA | - | -244.24 | -239.46 | -198.23 | -133.26 |
| Normalized EBITDA | - | -249.62 | -250.78 | -214.86 | -145.50 |
| EBIT | - | -257.15 | -256.78 | -214.44 | -148.87 |
| Interest Income | - | 0.34 | 0.02 | 0.17 | 0.08 |
| Interest Expense | - | 23.25 | 6.86 | 12.66 | 45.01 |
| Net Interest Income | - | -22.91 | -6.84 | -12.48 | -44.92 |
| Other Income Expense | - | 5.38 | 11.32 | 16.63 | 12.24 |
| Interest Income Non Operating | - | 0.34 | 0.02 | 0.17 | 0.08 |
| Interest Expense Non Operating | - | 23.25 | 6.86 | 12.66 | 45.01 |
| Net Non Operating Interest Income Expense | - | -22.91 | -6.84 | -12.48 | -44.92 |
| Pretax Income | - | -280.40 | -263.65 | -227.10 | -193.88 |
| Tax Provision | 13.41 | -0.08 | -0.15 | 0 | - |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0.01 | 0 | 0 |
| Net Income Continuous Operations | - | -280.32 | -263.49 | -227.10 | -193.88 |
| Net Income From Continuing And Discontinued Operation | - | -280.32 | -263.49 | -227.10 | -193.88 |
| Net Income From Continuing Operation Net Minority Interest | - | -280.32 | -263.49 | -227.10 | -193.88 |
| Net Income | - | -280.32 | -263.49 | -227.10 | -193.88 |
| Net Income Common Stockholders | - | -280.32 | -263.49 | -227.10 | -193.88 |
| Net Income Including Noncontrolling Interests | - | -280.32 | -263.49 | -227.10 | -193.88 |
| Normalized Income | - | -285.70 | -274.81 | -243.73 | -206.12 |
| Diluted NI Availto Com Stockholders | - | -280.32 | -263.49 | -227.10 | -193.88 |
| Basic Average Shares | 42.44 | 43.15 | 43.73 | 49.51 | - |
| Diluted Average Shares | 43.91 | 43.15 | 43.73 | 49.51 | - |
| Reconciled Depreciation | - | 12.91 | 17.32 | 16.22 | 15.62 |
| Reconciled Cost Of Revenue | - | 54.54 | 37.21 | 33.57 | 20.30 |
| Total Unusual Items | - | 5.38 | 11.32 | 16.63 | 12.24 |
| Total Unusual Items Excluding Goodwill | - | 5.38 | 11.32 | 16.63 | 12.24 |
| Special Income Charges | - | 0 | 0 | -2.10 | 0 |
| Impairment Of Capital Assets | - | 0 | 0 | 2.10 | 0 |
| Gain On Sale Of Security | - | 5.38 | 11.32 | 18.73 | 12.24 |
| General And Administrative Expense | - | 85.28 | 88.49 | 76.62 | 82.86 |
| Other Gand A | - | 85.28 | 88.49 | 76.62 | 82.86 |
| Other Operating Expenses | - | -6.68 | 0.40 | 0.86 | 0.18 |
| Provision For Doubtful Accounts | - | 0 | 0 | -5 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| REGENXBIO Inc.this co. | RGNX | $356M | -1.83 | 3.46 | -188.7% | -2.96 |
| Delcath Systems, Inc. | DCTH | $372M | 137.96 | 3.35 | 2.4% | 327.03 |
| Perspective Therapeutics, Inc. | CATX | $371M | -3.59 | 1.79 | -49.8% | -3.41 |
| Puma Biotechnology, Inc. | PBYI | $357M | 11.47 | 2.74 | 23.9% | 6.67 |
| Atea Pharmaceuticals, Inc. | AVIR | $354M | -2.23 |
| - |
| - |
| - |
| - |
| - |
| 1.28 |
| -57.5% |
| -1.43 |
| Greenwich LifeSciences, Inc. | GLSI | $347M | -21.99 | 136.99 | -623.1% | - |
| Larimar Therapeutics, Inc. | LRMR | $342M | - | 4.38 | -212.2% | - |
| Enanta Pharmaceuticals, Inc. | ENTA | $341M | -4.17 | 5.27 | -126.5% | -5.14 |
| Verastem, Inc. | VSTM | $339M | -1.62 | 5.93 | -366.2% | -1.07 |
| Peer Median | - | -2.23 | 3.86 | -92.0% | -1.25 | |